Search

Your search keyword '"David Tavan"' showing total 2 results
Start Over Author "David Tavan" Topic colorectal cancer
2 results on '"David Tavan"'

1. Colorectal Cancer Survivors Suffering From Sensory Chemotherapy-Induced Peripheral Neuropathy Are Not a Homogenous Group: Secondary Analysis of Patients’ Profiles With Oxaliplatin-Induced Peripheral Neuropathy

Author

Nicolas Kerckhove, Marie Selvy, Céline Lambert, Coralie Gonneau, Gabrielle Feydel, Caroline Pétorin, Agnès Vimal-Baguet, Sergey Melnikov, Sharif Kullab, Mohamed Hebbar, Olivier Bouché, Florian Slimano, Vincent Bourgeois, Valérie Lebrun-Ly, Frédéric Thuillier, Thibault Mazard, David Tavan, Kheir Eddine Benmammar, Brigitte Monange, Mohamed Ramdani, Denis Péré-Vergé, Floriane Huet-Penz, Ahmed Bedjaoui, Florent Genty, Cécile Leyronnas, Jérôme Busserolles, Sophie Trévis, Vincent Pinon, Denis Pezet, and David Balayssac

Subjects
chemotherapy-induced peripheral neuropathy, neuropathic pain, colorectal cancer, oxaliplatin, cluster analysis, Therapeutics. Pharmacology, RM1-950
Abstract

Oxaliplatin, a pivotal drug in the management of colorectal cancer, causes chemotherapy-induced peripheral neuropathy (CIPN) in a third of cancer survivors. Based on a previous cross-sectional study assessing oxaliplatin-related sensory CIPN in colorectal cancer survivors, a secondary analysis was designed to explore the possibility that different clusters of patients may co-exist among a cohort of patients with oxaliplatin-related CIPN. Other objectives were to characterize these clusters considering CIPN severity, anxiety, depression, health-related quality of life (HRQOL), patients’ characteristics and oxaliplatin treatments. Among the 96 patients analyzed, three clusters were identified (cluster 1: 52, cluster 2: 34, and cluster 3: 10 patients). Clusters were significantly different according to CIPN severity and the proportion of neuropathic pain (cluster 1: low, cluster 2: intermediate, and cluster 3: high). Anxiety, depressive disorders and HRQOL alteration were lower in cluster 1 in comparison to clusters 2 and 3, but not different between clusters 2 and 3. This study underlines that patients with CIPN are not a homogenous group, and that CIPN severity is associated with psychological distress and a decline of HRQOL. Further studies are needed to explore the relation between clusters and CIPN management.

Published
2021
Full Text
View/download PDF

2. Long-Term Prevalence of Sensory Chemotherapy-Induced Peripheral Neuropathy for 5 Years after Adjuvant FOLFOX Chemotherapy to Treat Colorectal Cancer: A Multicenter Cross-Sectional Study

Author

Vincent Pinon, Caroline Pétorin, Coralie Gonneau, Florent Genty, Valerie Lebrun-Ly, Cécile Leyronnas, Denis Pezet, Kheir Eddine Benmammar, Marie Selvy, Mohamed Ramdani, Vincent Bourgeois, Frédéric Thuillier, Sharif Kullab, Brigitte Monange, Mohamed Hebbar, Sergey Melnikov, Olivier Bouché, Thibault Mazard, Florian Slimano, Floriane Huet-Penz, Sophie Trevis, David Tavan, Denis Péré-Vergé, David Balayssac, Ahmed Bedjaoui, Gabrielle Feydel, Bruno Pereira, Agnès Vimal-Baguet, Jérôme Busserolles, Nicolas Kerckhove, Neuro-Dol (Neuro-Dol), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Clermont Auvergne [2017-2020] (UCA [2017-2020]), CHU Clermont-Ferrand, Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), Centre Hospitalier Universitaire de Reims (CHU Reims), Service d'Oncologie médicale [CHU Limoges], CHU Limoges, Institut de Recherche en Cancérologie de Montpellier (IRCM - U1194 Inserm - UM), CRLCC Val d'Aurelle - Paul Lamarque-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM), Centre hospitalier Saint Joseph - Saint Luc [Lyon], Groupe Hospitalier Mutualiste [Grenoble] (GHM), Microbes, Intestin, Inflammation et Susceptibilité de l'Hôte (M2iSH), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Clermont Auvergne [2017-2020] (UCA [2017-2020])-Centre de Recherche en Nutrition Humaine d'Auvergne (CRNH d'Auvergne)-Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement (INRAE), and Balayssac, David

Subjects
medicine.medical_specialty, peripheral neuropathy, Gabapentin, Colorectal cancer, Population, Pregabalin, lcsh:Medicine, colorectal cancer, Article, 03 medical and health sciences, chemistry.chemical_compound, 0302 clinical medicine, FOLFOX, Internal medicine, medicine, Duloxetine, cancer survivors, [SDV.NEU] Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC], education, education.field_of_study, business.industry, lcsh:R, oxaliplatin, General Medicine, medicine.disease, 3. Good health, Oxaliplatin, health-related quality of life, chemistry, Chemotherapy-induced peripheral neuropathy, 030220 oncology & carcinogenesis, [SDV.NEU]Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC], business, 030217 neurology & neurosurgery, medicine.drug
Abstract

(1) Background: Oxaliplatin is among the most neurotoxic anticancer drugs. Little data are available on the long-term prevalence and consequences of chemotherapy-induced peripheral neuropathy (CIPN), even though the third largest population of cancer survivors is made up of survivors of colorectal cancer. (2) Methods: A multicenter, cross-sectional study was conducted in 16 French centers to assess the prevalence of CIPN, as well as its consequences (neuropathic pain, anxiety, depression, and quality of life) in cancer survivors during the 5 years after the end of adjuvant oxaliplatin chemotherapy. (3) Results: Out of 406 patients, the prevalence of CIPN was 31.3% (95% confidence interval: 26.8&ndash, 36.0). Little improvement in CIPN was found over the 5 years, and 36.5% of patients with CIPN also had neuropathic pain. CIPN was associated with anxiety, depression, and deterioration of quality of life. None of the patients with CIPN were treated with duloxetine (recommendation from American Society of Clinical Oncology), and only 3.2%, 1.6%, and 1.6% were treated with pregabalin, gabapentin, and amitriptyline, respectively. (4) Conclusions: Five years after the end of chemotherapy, a quarter of patients suffered from CIPN. The present study showed marked psychological distress and uncovered a failure in management in these patients.

Published
2020
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results